# MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

> **NCT04552743** · PHASE2 · COMPLETED · sponsor: **Surbhi Sidana, MD** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MGTA-145
- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT04552743
- **Lead sponsor:** Surbhi Sidana, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-05
- **Primary completion:** 2021-07-22
- **Final completion:** 2022-06-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552743, "MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04552743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*